|
Ductal carcinoma in situ characteristics
|
All
|
Luminal A
|
Luminal B/HER2-
|
Luminal B/HER2+
|
HER2+/ER-
|
Triple negative
|
Unclassified
|
P valueb
|
P valuec
|
|---|
| |
n=458
|
n=186, (%)
|
n=33, (%)
|
n=74, (%)
|
n=61, (%)
|
n=27, (%)
|
n=77, (%)
| | |
|---|
|
Percentage of all
|
n=458
|
(40.6)
|
(7.2)
|
(16.2)
|
(13.3)
|
(5.9)
|
(16.8)
| | |
|
Percentage of all classified
|
n=381
|
(48.8)
|
(8.7)
|
(19.4)
|
(16.0)
|
(7.1)
|
-
| | |
|
Age mean, years
|
58.2
|
59.6
|
55.2
|
55.2
|
58.4
|
59.2
|
58.2
| | |
|
< 50
|
121(26.4)
|
48 (25.8)
|
12 (36.4)
|
23 (31.1)
|
14 (23.0)
|
8 (29.6)
|
16 (20.8)
|
0.38
|
0.42
|
|
50- 65
|
198 (43.2)
|
77 (41.4)
|
14 (42.4)
|
33 (44.6)
|
30 (49.2)
|
7 (25.9)
|
37 (48.0)
| | |
|
> 65
|
139 (30.3)
|
61 (32.8)
|
7 (21.2)
|
18 (24.3)
|
17 (27.9)
|
12 (44.4)
|
24 (31.2)
| | |
|
Detection mode
| | | | | | | | | |
|
Screening
|
345 (75.5)
|
134 (72.0)
|
27 (81.8)
|
67 (90.5)
|
44 (72.1)
|
18 (66.7)
|
55 (71.4)
|
0.10
|
0.16
|
|
Clinically
|
112 (24.5)
|
51 (27.4)
|
6 (18.2)
|
7 (9.5)
|
17 (27.9)
|
9 (33.3)
|
22 (28.6)
| | |
|
Tumor size
| | | | | | | | | |
|
Unifocal, mean, mm
|
16.7
|
14.9
|
16.5
|
16.4
|
21.8
|
19.9
|
16.3
|
0.93d
|
0.91d
|
|
Multifocal (number)
|
n=54
|
n=22
|
n=3
|
n=11
|
n=8
|
n=3
|
n=7
| | |
|
Histopathological grade
a
| | | | | | | | | |
|
Grade 1
|
37 (8.1)
|
23 (12.4)
|
1 (3.0)
|
1 (1.4)
|
1 (1.6)
|
1 (3.7)
|
10 (13.0)
|
<0.01
|
<0.01
|
|
Grade 2
|
203 (44.6)
|
121 (65.0)
|
17 (51.5)
|
20 (27.0)
|
6 (9.8)
|
9 (33.3)
|
32 (41.6)
| | |
|
Grade 3
|
215 (47.3)
|
42 (22.6)
|
15 (45.5)
|
53 (71.6)
|
54 (88.5)
|
17 (63.0)
|
35 (44.4)
| | |
|
Type of surgery
| | | | | | | | | |
|
Breast Conserving Surgery
|
359 (78.4)
|
151 (81.2)
|
28 (84.8)
|
57 (77.0)
|
41 (67.2)
|
22 (81.5)
|
60 (77.9)
|
0.17
|
0.27
|
|
Mastectomy
|
99 (21.6)
|
35 (18.8)
|
5 (15.2)
|
17 (23.0)
|
20 (32.8)
|
5 (18.5)
|
17 (22.1)
| | |
|
Postoperative radiotherapy
| | | | | | | | | |
|
Yes
|
161 (35.2)
|
63 (33.9)
|
17 (51.5)
|
27 (36.5)
|
23 (37.7)
|
9 (33.3)
|
22 (28.6)
|
0.42
|
0.33
|
|
No
|
297 (64.8)
|
123 (66.1)
|
16 (48.5)
|
47 (63.5)
|
38 (62.3)
|
18 (66.7)
|
55 (71.4)
| | |
-
aDCIS were classified according to the European Organization for Research and Treatment of Cancer (EORTC) system.
-
bP-values were calculated between molecular subgroups by IHC, unclassified lesions were excluded.
-
cP-values were calculated between molecular subgroups by IHC, unclassified lesions were included.
-
dChi-square test of categorical size groups (unifocal vs. multifocal).
